Clin Mol Hepatol > Volume 26(4); 2020 > Article |
|
Alcoholic liver disease | Complement component | Species |
---|---|---|
Alcoholic fatty liver disease | ||
Wlazlo et al. [5] | C3a | Human |
Bykov et al. [27] | C3 | Mouse |
Pritchard et al. [28] | C3, C5 | Mouse |
Zhong et al. [32] | C3 | Mouse and human |
Alcoholic hepatitis | ||
Shen et al. [37] | C1q, C3, C5, and C5aR | Human |
McCullough et al. [41] | Factor D | Mouse |
Fan et al. [42] | CFI and sC5b9 | Human |
Alcoholic hepatic fibrosis and cirrhosis | ||
Hillebrandt et al. [43] | C5 | Mouse and human |
Baumann al. [50] | C3 | Human |
Fudi Zhong
https://orcid.org/0000-0003-2606-1285
Songqing He
https://orcid.org/0000-0002-8966-2195
Immunopathogenesis of liver fibrosis in steatotic liver disease2024 April;30(2)
Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease2024 January;30(1)
Implications of comorbidities in nonalcoholic fatty liver disease2023 April;29(2)
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease2023 April;29(2)